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STUDY PROTOCOL Open Access
Examining the effects of adjuvant
chemotherapy on cognition and the impact
of any cognitive impairment on quality of
life in colorectal cancer patients: study
protocol
Marie-Rose Dwek*, Lorna Rixon, Alice Simon, Catherine Hurt and Stanton Newman
Abstract
Background: Research suggests that chemotherapy can cause deficits in both patients’ objectively measured and
self-reported cognitive abilities which can in turn affect their quality of life (QoL). The majority of research studies
have used post-treatment retrospective designs or have not included a control group in prospective cohorts. This
has limited the conclusions that can be drawn from the results. There have also been a disproportionate number of
studies focussed on women with breast cancer, which has limited the generalisability of the results to other cancer
populations.
Aim: This study aims to identify the extent and impact of chemotherapy-induced cognitive decline in colorectal
cancer patients. Possible associations with poorer QoL will also be explored.
Design: This will be a longitudinal controlled cohort study. Questionnaires measuring subjective cognitive
functioning, QoL, fatigue and mood, and neuropsychological assessments of objective cognitive function will be
collected pre-, mid- and post- chemotherapy treatment from a consecutive sample of 78 colorectal cancer patients
from five London NHS Trusts. A further 78 colorectal cancer surgery only patients will be assessed at equivalent
time points; this will allow the researchers to compare the results of patients undergoing surgery, but not
chemotherapy against those receiving both treatments.
Pre- and post-chemotherapy difference scores will be calculated to detect subtle changes in cognitive function as
measured by the objective neuropsychological assessments and the self-reported questionnaires. A standardised z-
score will be computed for every patient on each neuropsychological test, and for each test at each time point.
The post-chemotherapy score will then be subtracted from the pre-chemotherapy score to produce a relative
difference score for each patient.
ANCOVA will be used to compare mean difference z-scores between the chemotherapy and surgery-only groups
while controlling for the effects of gender, age, depression, anxiety, fatigue and education.
Discussion: The result from this study will indicate whether a decline in cognitive functioning can be attributed to
chemotherapy or to disease, surgical or some other confounding factor. Identification of risk factors for cognitive
deficits may be used to inform targeted interventions, in order to improve QoL and help patients’ cope.
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Background
Chemotherapy has been shown to increase survival
for a range of different cancers. This impact has im-
proved considerably over the years - most notably for
breast cancer and colorectal cancer (CRC) [1]. How-
ever, these drugs can cause severe side effects; the
most commonly perceived amongst the general public
have changed in recent years from nausea, vomiting,
loss of appetite and hair loss [2] to fatigue and psy-
chosocial QoL concerns [3]. This is due the fact that
there has been a significant reduction in
chemotherapy-associated toxicities [3] and the use of
very effective anti-nausea medications.
Many cancer patients also report a decline in cognitive
function following chemotherapy, colloquially referred
to as “chemofog” or “chemobrain”. Research in this area
suggests that memory, processing speed and executive
function may decline as a result of chemotherapy treat-
ments following surgery [4–9]. These cognitive deficits
could have implications for patients’ QoL, daily func-
tioning and work activity for long term cancer survivors
and are therefore an important concern [10]. The nat-
ural course and extent of any cognitive decline over time
and whether this decline translates into observable func-
tional difficulty for patients is relatively unknown.
“Chemobrain” was first identified by female breast
cancer survivors [11]. The majority of existing research
has taken place in this patient group [12, 13] where a
number of differing treatment combinations (e.g. anaes-
thetics and hormonal therapies) could augment the ef-
fects on cognitive dysfunction. Chemotherapy induced
cognitive impairment research has probably continued
to focus on the female breast cancer population because
it is the most frequently diagnosed cancer in women in
the world, comprising 18 % of all female cancers [11];
with 78 % of those diagnosed surviving for ten or more
years [1]. However, this focus has precluded the possibil-
ity of exploring gender differences in cognitive decline,
despite reports from other, mixed-gender, cancer popu-
lations (such as lung and CRC patients) that both men
and women are affected by the same constellation of
symptoms [11, 14].
CRC patients are an obvious population in which to
carry out this type of research in a mixed-gender setting.
CRC is the fourth most prevalent cancer in many devel-
oped countries, affecting men and women almost
equally [15]. Such patients have a comparatively high
survival rate. After surgery, 48 % of those with Stage
three bowel cancer will live for at least 5 years [16]. The
majority of resected Stage three CRC patients are offered
a 24-week course of adjuvant chemotherapy, adminis-
tered as part of standard treatment. This makes them a
good patient group for a longitudinal study examining
chemotherapy-induced cognitive changes over time.
One of the major limitations of earlier research has
been a failure to measure cognitive function prior to
chemotherapy treatment in order to provide a baseline
against which to detect changes over time and to deter-
mine whether there was impairment prior to the com-
mencement of the treatment [12, 17]. Measuring
cognitive function both before and after chemotherapy
treatment would identify any changes occurring due to
treatment.
The few recent longitudinal studies have produced
mixed findings [18–22]. One study reported a subtle
negative influence of chemotherapy on cognitive func-
tion in breast cancer patients compared to women re-
ceiving only adjuvant hormonal therapy [21]. One of the
few longitudinal studies in CRC patients reported no ef-
fect on cognitive function [22]. This study, however,
used only a small sample (N = 57)), whilst Cruzado and
colleagues (2014) [14] found that at the end of adjuvant
chemotherapy treatment for CRC there was an acute de-
cline in verbal memory in 56 % of patients. Neither of
these two studies used a control group which meant it
was not possible to establish whether any differences in
cognitive functioning were due to the general effects of
cancer and its symptoms or to the chemotherapy treat-
ment. Altogether this represents a limited research base
with a limited methodology and as a result it is not pos-
sible to draw firm conclusions about the extent and na-
ture of any cognitive decline arising from chemotherapy
treatment.
Our proposed study will address the limited generalis-
ability of the existing literature by examining a larger
CRC population, assessing patients pre-, mid- and post-
treatment. The design also follows one of the Inter-
national Cognition and Cancer Task Force (ICCTF) rec-
ommendations to compare “patients who receive the
same ensemble of treatments with or without chemother-
apy” [18] by including a surgery only control group
(www.icctf.com) [18].
All of the participants in this study will have under-
gone the same type of surgery but those in the control
group will not go on to have chemotherapy treatment.
However, it is expected that all participants will experi-
ence the same range of emotions such as anxiety and de-
pression that can accompany a cancer diagnosis and
consequent treatment. This research design will allow
the research team to detect the effect that adjuvant
chemotherapy may have on cognition in addition to sur-
gery. It will also permit the researchers to control for the
impact of a cancer diagnosis on levels of psychological
distress and QoL, both of which might affect cognitive
functioning. Although it is recognised that cancer sever-
ity may differ between the chemotherapy and surgery
only groups, these effects will be controlled for statisti-
cally. It would not be feasible to attempt to match
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participants for disease severity because those who are
offered adjuvant chemotherapy following surgery would
usually have a more advanced cancer stage than those
who require no further treatment after surgery.
The ICCTF also developed recommendations for a
core set of neuropsychological tests, common criteria for
defining cognitive impairment and cognitive changes,
and common approaches to study methods across such
research [18]. These will be followed in this study.
Study objectives
The aim of this study is to establish the extent of
chemotherapy-induced cognitive deficits and its effect
on QoL and daily functioning in both men and women
undergoing treatment for CRC. Specifically the study
will:
1. Determine the extent of cognitive deficits
attributable to adjuvant chemotherapy treatment by
conducting neuropsychological assessments in CRC
patients pre-, mid- and post-treatment.
2. Compare the extent and pattern of cognitive deficits
in CRC patients against a similar control group (e.g.
patients who have had colorectal surgery but do not
require chemotherapy).
3. Determine the effect of treatment-related cognitive
decline on QoL and psychological distress.
4. Examine the relationship between patients’ self-
reported cognitive functions and their objectively
assessed cognitive functions.
Methods
Design
This study will use a longitudinal design. Data will be
collected using neuropsychological assessments and QoL
questionnaires at three time points: post-surgery but
prior to chemotherapy treatment (‘T1’), between 12 and
14 weeks after first scheduled chemotherapy (‘T2’), and
3 months after last scheduled chemotherapy (‘T3’)
(Please see Fig. 1). A total of 156 participants (50 % of
whom will receive chemotherapy and 50 % will be non-
chemotherapy surgical patients) will be recruited from 5
NHS Healthcare Trusts across London. For those pa-
tients who are not receiving chemotherapy data will be
collected at T1 and then in parallel with the chemother-
apy group at T2 and T3.
Participants
Adult CRC patients under the care of the Consultant
Oncologists at five participating NHS Trusts with
London-based hospital sites who have had colorectal
surgery will be invited to take part in the study.
Patients who have had prior exposure to chemother-
apy or significant psychiatric or medical comorbidities,
which might affect ability to participate in the study, will
be excluded. Patients who are not sufficiently literate in
English will also be excluded as a failure to understand
English would make completion of the questionnaires
impossible. Only those patients over the age of 18 years
who have had surgery following a diagnosis of CRC will
be eligible to participate, provided that they are then of-
fered adjuvant chemotherapy treatment and start it at
least 3 weeks after surgery or no other cancer related
treatments at all and are fluent in written and spoken
English.
During the post-surgery follow-up appointment
nurses/trial co-ordinators at each location will provide a
consecutive series of patients (satisfying the inclusion
criteria) with information about the study. A research
assistant will also be available at that time to answer any
questions that the patient may have about the study.
Those patients who provide the researcher with
Fig. 1 Study measurement time points
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telephone numbers will be contacted after 48 h and
invited to participate in an interview, either at their
chemotherapy clinic or at home. This interview will
take place prior to the commencement of chemo-
therapy treatment for those in receipt of chemother-
apy and at a parallel point in time for the surgery
only control group (T1). At the beginning of the
interview the patient will be guided through the in-
formation sheet again and the consent form by the
researcher and written informed consent will be ob-
tained. In the event that a patient declines to pro-
vide the researcher with a telephone number or
refuses to take part he/she will not be contacted
again about the study.
The questionnaires and assessments will be completed
by the patient in the hospital at T1 and an appointment
for the subsequent assessments (T2, T3) will be made.
Patients’ participation in the research will take approxi-
mately 2 h and 15 min at T1 and 1 h 50 min at T2 and
T3 and will take place at the time of the appropriate out-
patient appointment or at an equivalent point in time
for the control group.
Measures
Pre-screening test
At T1, consented participants over the age of 65 will be
asked to complete the Montreal Cognitive Assessment
(MoCA) version 3 [23] as a pre-screening test in order
to exclude those with mild cognitive impairment (MCI)
from taking part in the study. In the event that such a
participant obtains a raw score of less than 26 they will
not progress into the study, as this is considered to be
the cut off point for MCI.
The following measures will be collected at T1, T2
and T3 unless otherwise specified:
Neuropsychological assessments
The following battery of assessments has been designed
to measure a wide range of cognitive domains and in-
cludes all of those recommended by the ICCTF [10]. All
measures are standardised, validated and taken from
published test batteries with healthy population norms,
which will provide the researchers with another import-
ant comparison:
i) The Hopkins Verbal Learning Test-Revised (HVLT-
R) [24] for verbal memory; this is a brief verbal
learning and memory test that includes delayed re-
call and recognition trials. Alternate forms will be
used at each of T1, T2 and T3.
ii) Trail Making Test (TMT) A and B [25] to measure
psychomotor speed and aspects of executive
function and spatial organisation, visual pursuits,
recall, and recognition.
iii)The Controlled Oral Word Association (COWA) of
the Multilingual Aphasia Examination [26] that
measures speeded lexical fluency requiring aspects
of executive function.
The above-recommended measures will be supple-
mented with the following:
iv) The Digit Span subtest of the Wechsler Adult
Intelligence Scales – Third Edition, (WAIS - III
Digit Span) [27] consisting of two mental activity
tests involving auditory attention and short term
memory retention capacity.
v) The Symbol Digit Modalities Test (SDMT) [28, 29]
assesses complex visual scanning and tracking [29].
It is a simple substitution task.
vi) Letter Cancellation of the Behavioural Inattention
Test (BIT) [30, 31].
vii) Grooved Pegboard Test [32, 33], a manual dexterity
test measuring visuo-motor coordination.
viii)The Benton Visual Retention Test (BVRT) [34] for
visual perception, visual memory and visuo-
constructive ability. There are three near-equivalent
forms (Forms C, D, and E) of the BVRT. Form C will
be used at T1, Form D at T2 and Form E at T3,
which will allow for retesting while minimizing prac-
tice effects. Administration A (of the 4 possible
methods) will be used throughout.
Self-reported cognitive functioning
Functional Assessment of Cancer Therapy-Cognitive
scale (FACT-Cog, Version 3) [35] is a validated self-
report measure of cognitive function. It evaluates mental
acuity, attention and concentration, memory, verbal flu-
ency, functional interference, deficits observed by others
but reported by the patient; change from previous func-
tioning, and impact on quality of life.
Mood
Anxiety and depression will be measured using the Hos-
pital Anxiety and Depression Scale (HADS) [36].
Fatigue
The Functional Assessment of Chronic Illness Therapy
– Fatigue (FACIT-F, version 4) [37] a 13-item self-report
subscale of the FACT-G (see below). The FACIT-F is a
well-validated quality of life instrument widely used for
the assessment of cancer-related fatigue in clinical trials
[37–40]. The items include physical and functional con-
sequences of fatigue [37].
Quality of life
The Functional Assessment of Cancer Therapy - General
(FACT-G, Version 4), will be used to measure 4 quality
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of life domains [38]: physical, emotional, family/social
and functional well being in the previous 7 days. Partici-
pants will also complete the 9-item FACT-C subscale
that evaluates symptoms related specifically to CRC.
IQ
This will only be measured at T1 using the Wechsler
Abbreviated Scale of Intelligence – Second Edition
(WASI –II) Vocabulary and Matrix Reasoning [41] to
assess background level of intellectual ability.
Socio-demographic information
This information will be collected at T1 via a structured
questionnaire and will include age, sex, employment (i.e.
full or part-time employment, retired and unemployed)
and marital status (married, cohabiting, single, separated,
divorced, widowed). Specific information relating to sur-
gery date, planned treatments and comorbidities will
also be obtained.
Medical records and treatment plan
Participants’ disease and treatment-related factors will
be recorded from medical records (including the type of
chemotherapy administered, any dose adjustments made,
the actual number of cycles completed, any neurotox-
icity experienced and the anti-emetic regimen) once the
participant has consented.
Sample size
A recent meta-analysis of chemotherapy and cognitive
function [42] estimated mean effect sizes in a range
of cognitive domains. The effect sizes ranged from d
=−0.11 to−0.51. A sample size calculation was per-
formed using GPower 3.1. Taking into consideration
the resource constraints of the study, the sample size
was calculated with the aim of detecting a medium
effect size. To detect an effect size of−0.26 with 80 %
power and a significance level of 0.05 at the final
time point, a minimum sample size of 120 partici-
pants was indicated. Based on medium effect sizes in
the meta-analysis, a sample size of 120 would allow
effects to be detected in the following domains: ex-
ecutive function, information processing speed, lan-
guage, motor function, verbal memory and visual
memory. However, it is acknowledged small effects
may not be detected in the following domains: atten-
tion and visuospatial skills. Assuming an overall attri-
tion rate of 22 % (based on SCOT trial attrition
rates1), a total sample size of 156 participants will be
sought (78 per group).
Analysis
In order to detect subtle changes in cognitive function,
pre- and post-chemotherapy difference scores will be
calculated. This approach has been successfully applied
in cardiac research exploring post-surgery cognitive
decline [43]. A standardised score (z-score) will be
computed for every patient on each neuropsycho-
logical test by dividing the test score by the standard
deviation of the pre-chemotherapy test score of all
study participants. A standardised score will be com-
puted for each test at all-time points using the pre-
chemotherapy standard deviation. The post-
chemotherapy standardised score will then be sub-
tracted from the pre-chemotherapy standardised score
to give a relative difference score for each patient. A
total z-score can then be computed for all neuro-
psychological tests.
ANCOVA will be used to compare mean difference z-
scores between the chemotherapy and surgery-only
groups while controlling for the effects of gender, age,
depression, educational level and extent of disease. This
method of analysis is preferable to conventional deficit/
no deficit analysis as it allows for detection of subtle
changes in cognition and accounts for pre-
chemotherapy cognitive performance [44] and will in-
crease the power of the analyses.
Multiple and logistic regression analyses will be used,
as appropriate, to explore the relationship between cog-
nitive impairment (total z-score) and quality of life
(FACT G & C), adjusting for age, gender, SES and anx-
iety and depression (HADS). Finally, correlation and re-
gression analyses will be also used to initially examine
the relationship between subjective (FACT-Cog) and ob-
jective (total z-score) cognitive impairment.
Ethics and acceptability feasibility
Ethical approval for the study was obtained from the
NHS Health Research Authority – NRES Committee
South-West Cornwall & Plymouth in August 2013.
All of the assessments are standardised and have been
widely used across many patient groups including cancer
patients. At the beginning of each assessment partici-
pants will be reminded that they have the right to with-
draw at any time and can avoid answering questions that
are felt to be too personal or intrusive. Participants will
be assured that any future treatment will not be affected
in any way should they choose to withdraw. However, in
the unlikely event that the assessments and content of
the questionnaires cause distress or any discomfort to
any of the participants, the researcher will remind the
participant that he/she is entitled to refuse to answer
any question that may cause upset or distress and that
he/she may stop and withdraw from the study at any
time. If they feel the need to have professional help they
will be encouraged to raise this with their consultant or
the consultant will be informed by the researcher if the
patient would prefer.
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Data management and data confidentiality
Confidentiality will be adhered to at all times. All ques-
tionnaires will be kept anonymous by assigning codes to
participants. All data will only be identified by that code,
not by the participant name or any other information
that could identify them. All questionnaires will be kept
in locked cabinets and/or password protected
computers.
Data will be collected, transferred and stored in com-
pliance with the NHS data protection requirements and
be managed by a data manager. The data manager will
also advise on current regulatory framework regarding
data protection and data management procedures in
compliance with the Data Protection Act 1998 and other
regulations. The data manager will design and set up a
bespoke database in MS Access, which will have inte-
grated data validation checks and a full audit trail. Pa-
tient identifiable and pseudonymised data will be stored
separately. The data manager will advise on and set up
data transfer systems and encryption systems so that all
patient identifiable data is encrypted. The data manager
will also advise on storage, back up and archiving of data
to ensure databases are regularly backed up to ensure
data is safeguarded from accidental loss. The study mas-
ter file and all study documentation will be archived for
10 years.
Discussion
At the time of writing, a feasibility study based on this
protocol is being carried out to assess participant num-
bers, attrition rates, recruitment procedures and
methodology.
The proposed study has a number of strengths. It is a
multi-site study that should provide access to large num-
bers of potential participants, thus ensuring that the
findings are more generalizable than results garnered
from a single site study. In contrast to other studies in
this area, this project is longitudinal and includes a com-
parison group in a gender-neutral cancer population.
This follows advice supplied by the ICCTF. The study
also uses all of the core neuropsychological tests recom-
mended by the ICCTF.
The study includes a pre-screening tool in order to
exclude anyone with pre-existing cognitive dysfunc-
tion from taking part. This has been done in few
studies to date, leaving open the possibility that the
results could be skewed by those who have pre-
existing cognitive conditions. The MoCA was specif-
ically designed as a rapid screening instrument for
MCI. It assesses different cognitive domains relative
to our study in 10 min, which should allow us to
preclude those potential participants with existing
cognitive deficits.
The study does also have some limitations. Treatment
regimes differ across participants such that some are
prescribed intravenous treatments every 2 weeks
whilst others take oral tablets every 3 weeks. Add-
itionally, treatment regimes can change over time for
some patients, and this may mean that the treatment
protocol will not be the same for all chemotherapy
patients. Secondary analysis will be conducted if no-
ticeable differences are identified between chemo-
therapy regimens although these results will need to
be interpreted with caution in the event that this
does occur as the comparisons will be
underpowered.
It is also acknowledged that the time from diagnosis to
start of treatment (particularly the period between the
surgery and the start of chemotherapy) is an emotionally
stressful time. Given that the anaesthetic from surgery
and general emotional distress can have an adverse effect
on cognitive functioning; it may be that testing during
this period will not provide a true index of abilities [45].
To control for this the measures of emotional distress
will be examined in relation to cognitive performance.
However as per the ICCTF’s recommendations, given
the logistical difficulties of carrying out the assessments
pre surgery, they are all being done after surgery but be-
fore adjuvant chemotherapy treatment begins.
Potential research implications
The result from this study will indicate whether a de-
cline in cognitive functioning can be attributed to
chemotherapy or to disease, surgical or some other con-
founding factor. Identification of risk factors for cogni-
tive deficits may be used to inform targeted
interventions, either compensatory or rehabilitating cog-
nitive strategies to manage cognitive deficits or challen-
ging unhelpful perceptions of cognitive functioning to
lessen the negative effects on QoL.
Potential benefits to research participants
There are no immediate benefits for the research
participants. There is anecdotal evidence to suggest
that cancer patients like to talk about ‘chemofog/
chemobrain’ so there is a small benefit in terms of
validation that such participants may feel by being
asked about this effect; however this may only be
apparent in their subjective views of their cognition.
There will be long term benefits to future cancer
patients in terms of the possibility of making a direct
contribution to the improvement of cancer patients’
lives that may ultimately lead to changes in care. For
example, results may lead to making the case for in-
tegrating neuropsychological assessments into the
treatment programme in order to identify those with
specific deficits and unfulfilled needs.
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Endnotes
1Personal communication with Dr Bridgewater of
UCLH.
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T3: Three months after last scheduled chemotherapy (i.e. approx. 9 months
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COWA: The controlled oral word association; SDMT: The symbol digit
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